Biogen Inc (NASDAQ:BIIB) Shares Bought by Wedge Capital Management L L P NC
Wedge Capital Management L L P NC boosted its stake in shares of Biogen Inc (NASDAQ:BIIB) by 21.6% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 145,599 shares of the biotechnology company’s stock after purchasing an additional 25,866 shares during the quarter. Wedge Capital Management L L P NC’s holdings in Biogen were worth $34,051,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently modified their holdings of the company. Trustcore Financial Services LLC grew its position in Biogen by 152.3% during the second quarter. Trustcore Financial Services LLC now owns 111 shares of the biotechnology company’s stock worth $26,000 after buying an additional 67 shares during the period. Resources Investment Advisors Inc. lifted its holdings in shares of Biogen by 500.0% in the first quarter. Resources Investment Advisors Inc. now owns 120 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 100 shares in the last quarter. Weaver Consulting Group purchased a new stake in shares of Biogen in the first quarter valued at about $28,000. Private Ocean LLC purchased a new stake in shares of Biogen in the first quarter valued at about $31,000. Finally, JJJ Advisors Inc. purchased a new stake in shares of Biogen in the second quarter valued at about $35,000. Institutional investors own 91.11% of the company’s stock.
Shares of BIIB traded down $5.87 on Wednesday, hitting $227.36. 36,099 shares of the stock traded hands, compared to its average volume of 1,871,920. The company has a quick ratio of 2.22, a current ratio of 2.46 and a debt-to-equity ratio of 0.49. The stock has a market cap of $42.14 billion, a price-to-earnings ratio of 8.74, a P/E/G ratio of 0.86 and a beta of 0.99. The firm has a 50 day moving average price of $235.76. Biogen Inc has a 1 year low of $216.12 and a 1 year high of $358.41.
Several analysts have issued reports on BIIB shares. Argus reaffirmed a “hold” rating on shares of Biogen in a report on Tuesday, May 7th. Mizuho reaffirmed a “hold” rating on shares of Biogen in a report on Thursday, July 25th. Citigroup reaffirmed a “neutral” rating on shares of Biogen in a report on Thursday, May 23rd. Cowen reaffirmed a “buy” rating and issued a $275.00 price target on shares of Biogen in a report on Tuesday, July 30th. Finally, Standpoint Research raised shares of Biogen from a “hold” rating to a “buy” rating in a report on Wednesday, June 5th. Three research analysts have rated the stock with a sell rating, twenty-four have given a hold rating and five have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $269.74.
Biogen Company Profile
Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis.
Further Reading: What is a Futures Contract?
Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc (NASDAQ:BIIB).
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.